42 results on '"Garassino M"'
Search Results
2. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
3. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
4. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
5. 26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
6. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
7. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
8. Assessment of anti-PD-1 antibody and immune complex binding to Fc gamma receptors and clinical implications
9. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306
10. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
11. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
12. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
13. Perioperative or postoperative therapy for resectable gastric cancer?
14. Predicting response of molecular targeted therapies: a still possible challenge?
15. New anti-emetic treatments
16. New strategies in colon cancer adjuvant therapy
17. Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways
18. Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan
19. Patient-centred approach in a multicenter national study (E-Lung): 405 lung cancer patients and caregivers, nurses and oncologists compared
20. SMO mutations role in malignant pleural mesothelioma: a negative prognostic factor, but possible new target?
21. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
22. S4 - Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways
23. 1469P - Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan
24. A34 - Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
25. A08 - SMO mutations role in malignant pleural mesothelioma: a negative prognostic factor, but possible new target?
26. A06 - Patient-centred approach in a multicenter national study (E-Lung): 405 lung cancer patients and caregivers, nurses and oncologists compared
27. Diagnostics
28. P1.25 Prospective Evaluation of the Role of Kras in Patients Treated with a Platinum Based Doublet
29. LBA2 Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC).
30. 85O Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC).
31. 532PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
32. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
33. LBA4 Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.
34. 23P Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
35. 101TiP PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy.
36. 82TiP IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy.
37. 188TiP Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial.
38. 160P EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy.
39. 150P Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy.
40. 53PImmune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme.
41. 139PAnalysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study.
42. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.